FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3046006129> ?p ?o ?g. }

• W3046006129 endingPage "124" @default.
• W3046006129 startingPage "124" @default.
• W3046006129 abstract "Patients diagnosed with metastatic sarcoma have limited options for achieving both local and distant tumor control. While SBRT can achieve local control, distant response rates remain low. There is limited evidence demonstrating the safety and efficacy for combining SBRT with concurrent PD-1 checkpoint blockade in metastatic sarcoma. In this prospective case-series, we examined five patients with metastatic sarcoma on pembrolizumab treated concurrently with SBRT from July 1, 2016–October 30, 2018. Acute and chronic toxicity were recorded using Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). SBRT-treated tumor control was assessed using Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). With median follow-up of 14.9 months, three patients with undifferentiated pleomorphic sarcoma, one with intimal, and one with chondroblastic osteosarcoma received SBRT with concurrent pembrolizumab to 10 sites of metastatic disease. No grade 5 toxicities were observed. There was a single incidence of transient grade 4 lymphopenia which resolved without intervention. Grade 3 toxicities included anemia, thrombocytopenia, lymphopenia and colitis. One tumor demonstrated local progression after SBRT, and all others remained stable or with response. In conclusion, combining SBRT with PD-1 inhibition appeared to be safe in this patient population. Expected high rates of treated-tumor local control after SBRT were observed. Two of five patients demonstrated either enhanced local tumor regression, or possible abscopal effect." @default.
• W3046006129 created "2020-08-03" @default.
• W3046006129 creator A5017738136 @default.
• W3046006129 creator A5040980527 @default.
• W3046006129 creator A5054512246 @default.
• W3046006129 creator A5061953236 @default.
• W3046006129 creator A5069486509 @default.
• W3046006129 creator A5071668167 @default.
• W3046006129 creator A5074549728 @default.
• W3046006129 creator A5077200623 @default.
• W3046006129 creator A5087974114 @default.
• W3046006129 creator A5089777560 @default.
• W3046006129 date "2020-06-04" @default.
• W3046006129 modified "2023-09-27" @default.
• W3046006129 title "The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma" @default.
• W3046006129 cites W1982488143 @default.
• W3046006129 cites W1984685643 @default.
• W3046006129 cites W2013333204 @default.
• W3046006129 cites W2019607817 @default.
• W3046006129 cites W2026835946 @default.
• W3046006129 cites W2032166347 @default.
• W3046006129 cites W2101653483 @default.
• W3046006129 cites W2344873536 @default.
• W3046006129 cites W2521278016 @default.
• W3046006129 cites W2560367415 @default.
• W3046006129 cites W2572174216 @default.
• W3046006129 cites W2587330058 @default.
• W3046006129 cites W2624275086 @default.
• W3046006129 cites W2730021240 @default.
• W3046006129 cites W2744257036 @default.
• W3046006129 cites W2761688153 @default.
• W3046006129 cites W2762797139 @default.
• W3046006129 cites W2767062261 @default.
• W3046006129 cites W2787553571 @default.
• W3046006129 cites W2787915872 @default.
• W3046006129 cites W2803707614 @default.
• W3046006129 cites W2889797706 @default.
• W3046006129 cites W2895125473 @default.
• W3046006129 cites W2905098668 @default.
• W3046006129 cites W2941990263 @default.
• W3046006129 doi "https://doi.org/10.1667/rade-20-00017" @default.
• W3046006129 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32845986" @default.
• W3046006129 hasPublicationYear "2020" @default.
• W3046006129 type Work @default.
• W3046006129 sameAs 3046006129 @default.
• W3046006129 citedByCount "9" @default.
• W3046006129 countsByYear W30460061292020 @default.
• W3046006129 countsByYear W30460061292021 @default.
• W3046006129 countsByYear W30460061292022 @default.
• W3046006129 countsByYear W30460061292023 @default.
• W3046006129 crossrefType "journal-article" @default.
• W3046006129 hasAuthorship W3046006129A5017738136 @default.
• W3046006129 hasAuthorship W3046006129A5040980527 @default.
• W3046006129 hasAuthorship W3046006129A5054512246 @default.
• W3046006129 hasAuthorship W3046006129A5061953236 @default.
• W3046006129 hasAuthorship W3046006129A5069486509 @default.
• W3046006129 hasAuthorship W3046006129A5071668167 @default.
• W3046006129 hasAuthorship W3046006129A5074549728 @default.
• W3046006129 hasAuthorship W3046006129A5077200623 @default.
• W3046006129 hasAuthorship W3046006129A5087974114 @default.
• W3046006129 hasAuthorship W3046006129A5089777560 @default.
• W3046006129 hasConcept C121608353 @default.
• W3046006129 hasConcept C126322002 @default.
• W3046006129 hasConcept C126838900 @default.
• W3046006129 hasConcept C142724271 @default.
• W3046006129 hasConcept C143998085 @default.
• W3046006129 hasConcept C197934379 @default.
• W3046006129 hasConcept C2776694085 @default.
• W3046006129 hasConcept C2777701055 @default.
• W3046006129 hasConcept C2777793932 @default.
• W3046006129 hasConcept C2778256501 @default.
• W3046006129 hasConcept C2778822529 @default.
• W3046006129 hasConcept C2779984678 @default.
• W3046006129 hasConcept C2780057760 @default.
• W3046006129 hasConcept C2781274730 @default.
• W3046006129 hasConcept C2908647359 @default.
• W3046006129 hasConcept C71924100 @default.
• W3046006129 hasConcept C99454951 @default.
• W3046006129 hasConceptScore W3046006129C121608353 @default.
• W3046006129 hasConceptScore W3046006129C126322002 @default.
• W3046006129 hasConceptScore W3046006129C126838900 @default.
• W3046006129 hasConceptScore W3046006129C142724271 @default.
• W3046006129 hasConceptScore W3046006129C143998085 @default.
• W3046006129 hasConceptScore W3046006129C197934379 @default.
• W3046006129 hasConceptScore W3046006129C2776694085 @default.
• W3046006129 hasConceptScore W3046006129C2777701055 @default.
• W3046006129 hasConceptScore W3046006129C2777793932 @default.
• W3046006129 hasConceptScore W3046006129C2778256501 @default.
• W3046006129 hasConceptScore W3046006129C2778822529 @default.
• W3046006129 hasConceptScore W3046006129C2779984678 @default.
• W3046006129 hasConceptScore W3046006129C2780057760 @default.
• W3046006129 hasConceptScore W3046006129C2781274730 @default.
• W3046006129 hasConceptScore W3046006129C2908647359 @default.
• W3046006129 hasConceptScore W3046006129C71924100 @default.
• W3046006129 hasConceptScore W3046006129C99454951 @default.
• W3046006129 hasIssue "2" @default.
• W3046006129 hasLocation W30460061291 @default.
• W3046006129 hasLocation W30460061292 @default.

• next